Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Level 5 - mechanism / opinion, no new human data
Narrative review of animal models and biological mechanisms with no primary human clinical data.
PubMed 20466987 · doi:10.1161/CIRCRESAHA.109.213447
What was done
This narrative review examined the biological and pathobiological roles of aldose reductase (AR) in hyperglycemia, ischemia-reperfusion injury, and diabetic cardiovascular complications. It assessed interspecies differences in AR expression and the utility of transgenic mouse models in replicating human pathophysiology.
What was found
The abstract reports no quantitative values. It qualitatively notes that AR expression is higher in humans and rats than in mice, with high expression linked to toxicity. Pharmacological inhibition of AR reduces injury during ischemia-reperfusion. Mice show similar pharmacological responses only when expressing a human AR transgene. Human AR expression exacerbates vascular disease in LDL receptor knockout mice under diabetic conditions. Conversely, AR genetic ablation increased atherosclerosis and hydroxynonenal in arteries, suggesting a dual role in detoxifying aldehydes.
Why it matters
Native mouse models fail to capture AR-mediated diabetic cardiovascular complications due to low baseline expression. Transgenic expression approximating human tissue levels is necessary to accurately model disease and evaluate AR-targeted therapeutics.
Limits
The paper is a narrative review presenting no new clinical data or systematic synthesis metrics. Discrepancies between AR toxicity via the polyol pathway and AR protection via aldehyde detoxification highlight unresolved physiological complexities across animal models.
Cited by
- supports Reduced blood flow during a heart attack stimulates local fructose synthesis in the heart via aldose reductase.